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Epithelial hyperplasia and metaplasia are common features of inflammatory and neoplastic disease, but the
basis for the altered epithelial phenotype is often uncertain. Here we show that long-term ciliated cell hyperplasia coincides with mucous (goblet) cell metaplasia after respiratory viral clearance in mouse airways. This
chronic switch in epithelial behavior exhibits genetic susceptibility and depends on persistent activation of
EGFR signaling to PI3K that prevents apoptosis of ciliated cells and on IL-13 signaling that promotes transdifferentiation of ciliated to goblet cells. Thus, EGFR blockade (using an irreversible EGFR kinase inhibitor designated EKB-569) prevents virus-induced increases in ciliated and goblet cells whereas IL-13 blockade (using
s-IL-13Rα2-Fc) exacerbates ciliated cell hyperplasia but still inhibits goblet cell metaplasia. The distinct effects
of EGFR and IL-13 inhibitors after viral reprogramming suggest that these combined therapeutic strategies
may also correct epithelial architecture in the setting of airway inflammatory disorders characterized by a
similar pattern of chronic EGFR activation, IL-13 expression, and ciliated-to-goblet cell metaplasia.
*OUSPEVDUJPO
Epithelial cell hyperplasia and metaplasia are common consequences of inflammation and may be associated with protective
as well as pathogenic outcomes. In the lung, airway epithelial
remodeling can be life threatening, since mucous cell metaplasia
is the foundation for hypersecretion that can obstruct the airway
lumen. Despite the critical nature of this process, little is known
about how mucous cell metaplasia develops in the setting of acute
or chronic inflammatory disease. Particularly, little is known
about the mechanism for what is likely the most common cause
of mucous cell metaplasia in the lung, i.e., respiratory viral infection, since previous work has focused on bacterial, allergic, and
carcinogenic stimuli. Perhaps because of the paucity of mechanistic information, no effective and specific pharmacologic treatment
is currently available to treat epithelial cell metaplasia in general or
mucous cell metaplasia in particular.
In this context, recent work on mucous cell metaplasia has often
focused on signaling pathways initiated by activation of the IL-13
receptor (IL-13R) and EGFR (also designated ErbB1 and HER1).
The experimental role of IL-13R was established when a decoy
receptor for IL-13 (soluble IL-13Rα2-Fc) was found to inhibit allergen-induced mucous (goblet) cell formation in mice (1, 2). These
reports have been followed by evidence that IL-13 can directly drive
mucin gene expression in airway epithelial cells cultured under
physiologic conditions and in vivo (3–6). Moreover, IL-13 is often
overexpressed in the setting of mucous cell metaplasia in asthma
Nonstandard abbreviations used: CCSP, Clara cell secretory protein; CLCA, calcium-activated chloride channel; COPD, chronic obstructive pulmonary disease;
IL-13R, IL-13 receptor; mTEC, mouse tracheal epithelial cell; PCNA, proliferating cell
nuclear antigen; SeV, Sendai virus; SeV-UV, UV-inactivated SeV; z-VAD-fmk, z-Val-AlaAsp fluoromethylketone.
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J. Clin. Invest. 116:309–321 (2006). doi:10.1172/JCI25167.
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and chronic obstructive pulmonary disease (COPD) (7–9). The
downstream events connecting IL-13R activation to mucin gene
expression are incompletely defined, but preliminary work with
inhibitors indicates requirements for MEK/ERK, p38 MAPK, and
PI3K activation, at least in vitro (5). These effects appear to develop
in concert with calcium-activated chloride conductance to promote
fluid secretion and consequent mucociliary clearance (10). This
function may be connected to expression of a calcium-activated
chloride channel (CLCA) that is specific for goblet cells (11). Thus,
IL-13 appears to directly stimulate epithelial mucin formation, but
the type of epithelial cell that is targeted and the cellular process for
mucous cell differentiation remain less certain.
Similar to the case for IL-13, the pathway for EGFR activation leading to mucous cell metaplasia is not well defined. First,
altered EGFR expression has been found in humans with asthma
(known to exhibit goblet cell metaplasia) and in animal models of
asthma, but expression has been variably found on goblet cells as
well as other types of airway epithelial cells, e.g., squamous, basal,
ciliated, and Clara cells (12–21). This variability is further complicated by uncertainty over the specificity of anti-EGFR antibodies
and their capacity to define EGFR activation status. Second, similar to the case for IL-13, animal models often rely on allergen challenge that appears to drive mucin gene expression predominantly
in cells that resemble Clara cells by morphology (22–24). These
cells express Clara cell secretory protein (CCSP), but tracking cell
lineage is complicated by EGFR and IL-13–dependent stimulation
of CCSP expression, perhaps in multiple cell types (25). Third,
extensions of these studies to signaling mechanisms have often
been performed in transformed cell lines (17, 19, 26–31), and even
when primary airway epithelial cells were used, cultures were not
fully differentiated under physiologic conditions to a respiratory
epithelium (18, 32–34). Thus, 1 biochemical scheme from this
work suggests that IL-13 stimulation of EGFR signaling leads to
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mucin gene expression (21), but studies of airway epithelial cells 3FTVMUT
under physiologic conditions show that IL-13 fully stimulates Persistent activation of EGFR on ciliated epithelial cells. Common human
goblet cell metaplasia despite EGFR blockade (5). Thus, there is paramyxoviruses often replicate poorly in mice, but mouse parainlikely a fundamental requirement for EGFR activation in muco- fluenza virus (Sendai virus; SeV) replicates with high efficiency in
ciliary differentiation (5, 35), but how this requirement may be the bronchiolar mucosa, with consequent induction of immunelinked to the modification of epithelial cell growth or differen- response gene expression, immune cell infiltration, and damage of
tiation during cytokine stimulation, inflammation, and/or infec- the epithelium (37). This host response allows for complete clearance
tion still needed to be defined. Fourth, the whole subject of EGFR of SeV by 10–12 days after inoculation (36, 38). The injury is followed
regulation of cell survival, which appears so critical for neoplasia, by epithelial repair and restoration of normal airway architecture in
has not yet been taken into account in the process of epithelial some mouse strains (see below) but can be followed by long-term
cell metaplasia during inflammatory disease. Finally, previous (likely permanent) goblet cell metaplasia in C57BL/6J mice that
approaches concentrate predominantly on the acute phase of epi- appears at 21 days after inoculation (36). Since EGFR signaling is
thelial remodeling without addressing chronic goblet cell meta- broadly implicated in epithelial remodeling, we assessed EGFR
plasia that may be found in hypersecretory airway diseases
such as asthma and COPD.
To address these issues, we studied a mouse model of airway epithelial remodeling that is inducible by viral infection
and features a delayed but permanent switch to goblet cell
metaplasia (36). The observed patterns of acute infection
and chronic remodeling were characterized in detail, in particular the dissociation between the acute antiviral response
that allows for viral clearance versus the subsequent postviral response manifested by chronic airway hyperreactivity
and goblet cell metaplasia (36, 37). When we examined the
behavior of EGFR signaling in this model, we detected acute
activation of EGFR during the epithelial repair phase that
was replaced by chronic activation of EGFR localized to ciliated epithelial cells. This chronic activation coincides with
ciliated cell hyperplasia without a requirement for ongoing epithelial proliferation. Both ciliated cell hyperplasia
and goblet cell metaplasia could be prevented by treatment
with a new irreversible inhibitor of EGFR tyrosine kinase.
These findings suggested a role for EGFR-dependent signaling pathways in ciliated cell survival, and we subsequently
detected and defined such a mechanism that proceeds via
PI3K/Akt signaling to selectively protect ciliated epithelial
cells from apoptosis. However, this mechanism did not readily explain a requirement for EGFR signaling in goblet cell
metaplasia until we next detected ciliated cells that appeared
to transdifferentiate to goblet cells under pressure from IL-13
stimulation. Thus, in vivo inhibition of IL-13 signaling
blocks goblet cell formation but also, by preventing transdifferentiation, further increases the level of ciliated cell
hyperplasia. The results thereby provide a new paradigm
for chronic goblet cell metaplasia that depends on persistent activation of 2 complementary pathways: EGFR-PI3K
signals that protect against ciliated cell apoptosis and IL-13
signals that promote ciliated to goblet cell transdifferentiation. This scheme is consistent with EGFR and IL-13 effects
on epithelial cells as well as evidence of ciliated cell EGFR 'JHVSF
activation, IL-13 production, and goblet cell metaplasia 1FSTJTUFOU&('3BDUJWBUJPOPODJMJBUFEFQJUIFMJBMDFMMTBGUFSWJSBMJOGFDUJPO " 
in the epithelium of asthmatic subjects. Therefore, treat- 3FQSFTFOUBUJWFQIPUPNJDSPHSBQITPGBJSXBZTFDUJPOTGSPN$#-+NJDF
ment to fully restore normal epithelial behavior in asthma PCUBJOFEBUEBZTBGUFSJOPDVMBUJPOXJUI4F7PSBOFRVJWBMFOUBNPVOUPG
and related hypersecretory conditions such as COPD may 4F767BOEUIFOJNNVOPTUBJOFEGPS&('3BOEQ&('3BTXFMMBTDPNQF
need to be directed at combined correction of EGFR- and UJUJPOCZGPMEBOUJHFO "H FYDFTT4DBMFCBSμN # 3FQSFTFOUBUJWF
QIPUPNJDSPHSBQITPGBJSXBZTFDUJPOTPCUBJOFEGSPNNJDFBUEBZTBGUFS
IL-13–dependent abnormalities in airway epithelial cell
JOPDVMBUJPOXJUI4F7BOEUIFOTVCKFDUFEUPJNNVOPGMVPSFTDFOUTUBJOJOHGPS
survival and differentiation. In that regard, we establish the &('3 βUVCVMJO $$41 BOE.6$"$BMPOFBOEJODPNCJOBUJPO1SJNBSZ
efficacy of an orally active and irreversible EGFR inhibitor BOUJ&('3"CCJOEJOHXBTEFUFDUFECZBOUJ$:"C SFEGMVPSFTDFODF XIJMF
and a soluble IL-13 decoy to prevent these abnormalities in PUIFSTXFSFEFUFDUFECZBOUJ'*5$"C HSFFOGMVPSFTDFODF 4DBMFCBSμN
epithelial architecture.
4JNJMBSSFTVMUTXFSFPCUBJOFEGPSNJDFUSFBUFEXJUI4F767
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SFQSFTFOUNFBO4&. 4JHOJGJDBOUEJGGFSFODFGSPN4F767DPOUSPM

behavior in mouse airway epithelium in this model. Western blot
analysis indicated that anti-EGFR and anti–phospho-EGFR (anti–
p-EGFR) antibodies specifically recognized the receptor in airway tissue samples (data not shown). Immunostaining of airway tissue with
anti-EGFR antibody indicated that EGFR expression was predominantly localized to the apical membrane of ciliated epithelial cells,
although other cell types (e.g., basal cells and airway smooth muscle
cells) were also weakly immunostained (Figure 1A). No significant
difference was observed in the pattern or the level of anti-EGFR
immunostaining between mice infected with SeV and control mice
that were inoculated with UV-inactivated SeV (SeV-UV). In contrast,
immunostaining for p-EGFR (using an anti–p-EGFR antibody that
recognizes phosphorylated Tyr845) indicated that levels of activated
EGFR were persistently increased at 21 days after inoculation with
SeV compared with uninoculated or SeV-UV–inoculated control
mice. Similar to the pattern for EGFR expression, p-EGFR was also
localized mainly to the apical surface of ciliated epithelial cells, but
in this case, apical cell staining was also accompanied by corresponding nuclear staining in this same ciliated cell population (Figure 1A).
The Journal of Clinical Investigation

Other cell types (e.g., basal cells) were also weakly immunostained in
nuclear and cytosolic locations. These findings are consistent with
reports of nuclear translocation of activated EGFR (39). This pattern of immunostaining indicated that the initial EGFR antibody
recognizes predominantly the unphosphorylated receptor. For both
antibodies, immunostaining was completely abolished by preabsorption with corresponding antigen. In addition, normal rabbit IgG was
used as a negative isotype control and showed no significant signal
above background. In further support of EGFR expression localized predominantly to ciliated epithelial cells, double labeling and
immunofluorescence detected by laser scanning confocal microscopy
indicated that EGFR colocalized with a marker for ciliated epithelial
cells (i.e., β-tubulin) but not with markers for Clara cells (i.e., CCSP)
or goblet cells (i.e., MUC5AC) in mouse airways (Figure 1B).
This pattern of EGFR immunostaining found in mice was similar to the one in human subjects. In particular, EGFR expression
was also localized to the apical cell membrane of ciliated epithelial
cells in normal and asthmatic subjects, and p-EGFR was increased
in asthmatic subjects that also manifested goblet cell metaplasia
(Supplemental Figure 1; supplemental material available online
with this article; doi:10.1172/JCI25167DS1). Expression of p-EGFR
was similarly localized to the apical portion of ciliated epithelial
cells, and expression was accompanied by corresponding nuclear
staining in the same ciliated cells. Additional, albeit weaker, p-EGFR
immunostaining was also present on basal cells in both normal and
asthmatic subjects. This finding was also consistent with previous
reports of EGFR expression in this basal cell population (12, 15,
18, 19). The present pattern of EGFR localization to the apical and
ciliary regions of ciliated epithelial cells is consistent with observations in developing lung and other sites (40–43). Others report
basolateral localization of EGFR in some epithelial tissues (e.g., gut
and kidney) (44, 45) and in airways (46); we find expression at this
location as well but without any predilection for ciliated cells. In
either case, the consistent finding of EGFR and p-EGFR expression
on ciliated epithelial cells in mouse and human airways led us to
continue these studies in a mouse model of asthma, where experimental conditions and genetic background are more completely
controlled and more extensive lung sampling is possible.
EGFR as a critical component in epithelial remodeling. To define a functional role for persistent EGFR signaling on ciliated epithelial cells,
lung sections were subjected to immunostaining with markers for
ciliated epithelial cells, Clara cells, and goblet cells. Quantitative analysis of cell types found in the airway epithelium indicated that SeVinfected mice developed increases in ciliated and goblet cells and concomitant decreases in Clara cells at day 21 (but not by day 12) after
inoculation compared with control mice inoculated with SeV-UV
(Figure 2). We next determined whether EGFR signaling was necessary for these observed changes in epithelial architecture. For these
studies, we used a new irreversible EGFR inhibitor (EKB-569) that
selectively inhibits EGFR signaling in airway epithelial cells in vitro
(Supplemental Figure 2). To achieve blockade in vivo, we administered EKB-569 orally each day from postinoculation day 10 (so as not
to interfere with viral clearance or epithelial repair) through day 21
(when the remodeling response developed). Under these treatment
conditions, EKB-569 also blocked EGFR signaling in vivo (Supplemental Figure 2). Moreover, when provided in this way, EGFR
inhibitor treatment also helped to correct all 3 aspects of epithelial
remodeling. Specifically, we observed complete blockade of ciliated
cell increases and Clara cell decreases and partial but significant inhibition of goblet cell metaplasia (Figure 2B). EKB-569 treatment had
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no effect on the total number of airway epithelial cells (cytokeratinstaining cells were 133 ± 3 after vehicle and 137 ± 5/mm basement
membrane after drug treatment on postinoculation day 21), consistent with compensatory changes in other epithelial cell (e.g., basal
and Clara cell) populations. Based on immunohistochemical data
showing localization of EGFR and β-tubulin expression together
in the same ciliated cell population, we expected that EGFR blockade might influence ciliated cell hyperplasia. However, the effect of
interrupting EGFR signals on goblet cell (or Clara cell) levels was
unexpected based on the relative absence of activated EGFR expression on either of these cell types. Further experiments were therefore
designed to better understand the mechanisms underlying the role
of EGFR in chronic epithelial remodeling.
We reasoned that epithelial hyperplasia could either be a result
of increased proliferation or decreased cell death. We therefore initially looked for evidence of increased proliferation in mice with
epithelial remodeling. As noted previously, there was transient epithelial proliferation (marked by BrdU labeling) during days 5–12
after infection (Figure 3, A and B, and ref. 47). The same pattern of
immunostaining was found for Ki-67 and proliferating cell nuclear
antigen (PCNA) proliferation markers (data not shown). This proliferative response likely allows for replacement of host cells that
suffer direct cytopathic effects and immune-mediated cell death in
the wake of viral replication (38). Not surprisingly, this repair phase
is accompanied by EGFR activation in epithelial cells (generally
basal cells) as well as subepithelial (likely immune) cells (Figure 3C).
However, by postinoculation day 21, there was no longer evidence
of an ongoing proliferative response, since cellular proliferation
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was no different than in noninoculated control mice (Figure 3,
A and B). Moreover, this replacement phase (marked by BrdU uptake
and EGFR activation in the basal cell compartment) was the same
in a strain of mice (Balb/cJ) that does not develop long-term epithelial remodeling (Figure 3, A–E). Thus, this transient proliferative
response could not account for the subsequent long-term remodeling that was found only in genetically susceptible (C57BL/6J)
mice. Moreover, the lack of an ongoing epithelial proliferative
response suggested that ciliated cell hyperplasia might reflect a
selective increase in EGFR-dependent cell survival based on suppression of cell death in this subpopulation of epithelial cells.
EGFR signaling and ciliated cell survival in culture. To determine
whether EGFR provides necessary survival signals to ciliated epithelial cells, we next analyzed EGFR blockade in tissue culture
where macrophage clearance would not obscure detection of apoptotic cells and where signaling events could be better defined. Initial
experiments aimed to determine whether EGFR was localized to
ciliated epithelial cells in culture as was found in vivo. We therefore
reconstituted the epithelial system in vitro using air-liquid interface
cultures of airway epithelial cells harvested from mouse trachea. In
this system, ciliated (β-tubulin–positive) cells represented 45% ± 1%
of the total cell population, a level that was similar to normal mouse
airways (36% for large-sized airways) and to values for mouse tracheal specimens reported previously (48). As was the case in vivo,
the ciliated epithelial cells in culture exhibited constitutive expression of EGFR and p-EGFR along the apical cell membrane; p-EGFR
was found in this location as well as a nuclear one following activation by ligand (Figure 4A and data not shown). Others reported
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that EGFR may also be localized to the basolateral cell membrane
in cultured airway epithelial cells (46), but any differences could
depend on culture conditions, receptor heterogeneity that influences recognition by different antibodies, or receptor abundance
that may influence apical versus basolateral localization (49).
We next defined the role of EGFR signaling in ciliated epithelial
cell growth and survival using treatment with selective inhibitors.
Initial experiments to validate inhibitor specificity used cultures
that were first removed from complete medium and then stimulated with EGF to maximize EGFR-dependent signals. Under these
conditions, we found that EGFR tyrosine kinase inhibition with
PD153035 blocked all downstream signals, while PI3K inhibition
with LY294002 blocked phosphorylation of Akt, and MEK1/2 inhibition with PD98059 blocked phosphorylation of ERK1/2 (Figure 4B).
The next experiments determined the effect of these EGFR signals
on ciliated cell survival. We found that treatment with PD153035
caused a dose-dependent loss of ciliated cells out of proportion to
the consequent decrease in total epithelial cells (Figure 4C). Similar
results were obtained with another EGFR-specific inhibitor, AG1478
(data not shown). Recognizing that EGFR activation triggers several
downstream signaling pathways, we next treated mouse tracheal epithelial cell (mTEC) cultures with inhibitors of PI3K and MEK1/2 and
found that only treatment with LY294002 caused a similar loss of
ciliated epithelial cells (Figure 4D). Since this culture system does not
exhibit significant cell growth at high density, it appeared likely that
the loss of ciliated epithelial cells was due to decreased cell survival.
Accordingly, we next tested whether blockade of EGFR signaling
led to concordant changes in the level of apoptosis. In parallel with
loss of ciliated epithelial cells, we also observed rapid activation of
The Journal of Clinical Investigation

caspase-3 and TUNEL-positive cells (within 6 hours) in the same
pattern that we had observed for cell loss, i.e., when EGFR or PI3K
but not MEK1/2 signaling was blocked (Figure 5A). In this setting,
TUNEL-positive cells were undergoing apoptosis, since this process
was blocked by treatment with the caspase-inhibitor z-Val-Ala-Asp
fluoromethylketone (z-VAD-fmk) (Figure 5B) and was associated
with caspase-3 and caspase-9 cleavage/activation (Figure 5C) and
loss of mitochondrial membrane potential (Figure 4D). These results
therefore define an EGFR signaling pathway that protects against
ciliated cell apoptosis via selective PI3K signaling to downstream factors that prohibit mitochondrial dysfunction and consequent programmed cell death. As discussed below, the findings stand in some
contrast to reports of EGFR and other receptor signals to ERK1/2
that prevent cell death under other circumstances (38, 50, 51).
EGFR signaling and goblet cell metaplasia in vitro and in vivo. As noted
above, the actions of EGFR signaling on ciliated cells did not readily explain the effect of EGFR blockade on goblet cell metaplasia in
vivo. In particular, selective EGFR expression and consequent survival function on ciliated cells could account for inhibition of ciliated cell hyperplasia but could not account directly for blockade of
goblet cell metaplasia as well. Despite the low levels of EGFR expression on goblet cells, we next questioned whether EGFR might still
have a similar functional effect on goblet cell survival. To test this
possibility, we took advantage of concomitant studies that defined
IL-13 dependence of goblet cell metaplasia after viral infection (E.Y.
Kim and M.J. Holtzman, unpublished observations). This effector
pathway therefore overlaps with that established in studies of mucin
production after allergen challenge (1, 2). In addition, we recognized
the capacity of IL-13 treatment to stimulate goblet cell formation in
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airway epithelial cells cultured from guinea pigs and humans (3–5) as
well as mice (J.D. Morton and M.J. Holtzman, unpublished observations). Cultured mTECs were therefore treated with IL-13, and the
subsequent development of goblet cells was marked by expression of
MUC5AC. Cell death was tracked with activation of caspase-3, since
the procedure for the TUNEL reaction appears to decrease mucin
content. In contrast to ciliated cells, we found that goblet cells did
not exhibit increased rates of cell death in response to EGFR inhibition (Figure 6A). Quantifying the level of active caspase-3 cells in
MUC5AC-positive versus MUC5AC-negative populations indicated
that the level of apoptosis was similar in goblet cells with or without
EGFR blockade, whereas the nongoblet cells (i.e., ciliated epithelial
cells) exhibited significant caspase-positive staining under these
treatment conditions (Figure 6B). Moreover, the level of nongoblet
cell death was similar with or without IL-13 treatment, indicating
that the death pathway in ciliated cells is not influenced by IL-13–
dependent actions on goblet cell formation.
Since EGFR blockade caused no effect on goblet cell survival
in vitro, we reasoned that the potent effects of EGFR blockade
on goblet cell metaplasia in vivo might be downstream of EGFR
blockade of ciliated cell hyperplasia. Support for that possibility
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was obtained when we found that IL-13 treatment led to the development of cells that transiently shared characteristics of ciliated
and goblet cells. Thus, electron microscopy of mTEC cultures provided evidence of a subset of cilia-goblet cells with preservation of
cilia and the gradual development of mucous granules under the
influence of IL-13 (Figure 7). These transitional cells were most
prominent early (1–2 days) after initiation of IL-13 treatment,
while mature goblet cells without cilia were most abundant at
later times (5 days) after treatment. The morphologic characteristics of cilia-goblet cells under these conditions appear quite similar to ciliated cells containing mucous granules found by electron
microscopy in airways of allergen-challenged mice (23).
Since airway epithelial cultures were established under conditions
that required IL-13 treatment to promote goblet cell formation in an
environment that would otherwise produce ciliated cells, these ciliagoblet cells were likely being redirected by IL-13 to transdifferentiate
from a ciliated to goblet cell phenotype. The possibility that similar transdifferentiation also developed in vivo was next confirmed
in sections taken from mice exhibiting goblet cell metaplasia after
inoculation with SeV. Confocal microscopy indicated that, while
the majority of ciliated or goblet cells expressed either β-tubulin or
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development of goblet cell metaplasia (Figure 8D). Under these conditions, we found that sIL-13Rα2-Fc treatment was highly effective
in preventing virus-induced goblet cell metaplasia (Figure 8E). However, in some contrast to EGFR blockade, sIL-13Rα2 treatment also
caused a further increase in the level of ciliated cell hyperplasia (consistent with a block in their movement to goblet cells) and no change
in Clara cell levels (consistent with the possibility that goblet cell
formation derives at least in part from ciliated cell rather than Clara
cell populations). We cannot fully exclude the possibility that other
cellular sources (e.g., Clara cells or basal cells) may also contribute to
goblet cell metaplasia in this setting, but the close match of ciliated
cell increase to goblet cell decrease after IL-13 blockade suggests that
transdifferentiation of the ciliated cell population is a significant
pathway for goblet cell metaplasia under these conditions. Indeed,
together with previous and present evidence of Clara cell expression
of mucin genes, the present results may simply provide evidence of
additional plasticity of epithelial cell differentiation.
In a final 2 sets of experiments, we again extended our findings
from mice to studies of human subjects. In the first set of experiMUC5AC, respectively, there was a subpopulation of epithelial cells
that expressed both β-tubulin and MUC5AC (Figure 8A). Similarly,
confocal images also indicated that, in general, ciliated but not goblet cells expressed EGFR, but there was an additional subpopulation
of cells that expressed both EGFR and MUC5AC (Figure 8B). In each
case, multiple confocal sections along the z axis and 3D reconstruction were used to confirm colocalization within a single cell. The
subpopulation expressing MUC5AC and β-tubulin and or MUC5AC
and EGFR appeared to be in transition, since they did not often reach
their characteristic shape and position at the lumenal surface of the
mucosal epithelial layer as was found for mature goblet cells. In addition, in these transitioning cells, the mucous granules were often
localized in a more basal compartment of the cells versus a more
apical location for fully differentiated goblet cells. This morphologic
behavior also suggests that these cilia-goblet cells represent goblet
cell precursors. As noted previously for allergen-induced goblet cell
metaplasia, we also detected a subpopulation of epithelial cells with
coexpression of CCSP and MUC5AC (Figure 8C) at levels comparable to detection of cilia-goblet cells (Figure 8E).
We next aimed to establish whether IL-13 also promotes cilia to goblet cell formation in vivo as we had observed in vitro. For these experiments, we took advantage of a recombinant soluble IL-13R α2 Fc
fusion protein (designated sIL-13Rα2-Fc) that acts as a decoy receptor to specifically block IL-13 action when delivered to mice (1, 2).
Treatment conditions were chosen to be similar to those used for
EGFR blockade, so treatment extended from day 12 to 21 after viral
inoculation. This time frame also coincides with the induction of
IL-13, mCLCA3, and MUC5AC gene expression in concert with the
The Journal of Clinical Investigation
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ments, we analyzed airway tissue from a group of COPD patients
that exhibited markedly increased levels of goblet cells in the airway
and provided adequate lung tissue for analysis at the time of lung
transplantation. By applying the same immunostaining protocol
for immunofluorescence and confocal microscopy as for the mouse
model, we found that sections of lung explants from COPD patients
also exhibited evidence of β-tubulin–MUC5AC coexpression in a
subset of airway epithelial cells (Figure 9A). We did not detect lumenal staining for β-tubulin in human (or mouse) airways, consistent
with the proposal that cilia may be processed by endosomal degradation rather than shedding. As noted previously (52), CCSP-MUC5AC
coexpression was also found in a subset of epithelial cells. In the
second set of experiments, we again applied the strategy that we
used for mouse studies and analyzed the behavior of human airway
epithelial cells in air-liquid interface culture conditions without or
with IL-13. In this case, we found that airway epithelial cells cultured
from COPD patients led to the development of a subset of cells that
coexpressed β-tubulin and MUC5AC under the influence of IL-13.
As noted previously, β-tubulin is localized within the basal bodies
of ciliated cells (53) and so provides even closer colocalization with
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MUC5AC found in mucous granules. The same pattern of IL-13–
induced coexpression of ciliated and goblet cell markers was found
in airway epithelial cells cultured from otherwise healthy lung transplant donors in response to IL-13, even within the first day of IL-13
treatment (Figure 9C). As we did for the studies of mouse and human
tissue, we examined multiple confocal images along the z axis and
3D reconstruction to establish colocalization of ciliated and goblet
cell markers within a single cell. Thus, similar to our experience for
EGFR activation in human subjects, we found that the downstream
mechanism for goblet cell metaplasia found in the mouse model, i.e.,
IL-13–driven ciliated-to-goblet cell transdifferentiation, appears to
have a counterpart in hypersecretory human disease.
%JTDVTTJPO
The present report provides initial evidence that transient viral
bronchiolitis causes a long-term switch to ciliated cell hyperplasia
as well as goblet cell metaplasia and that the hyperplastic ciliated
cell population exhibits persistent EGFR activation without proliferation. This finding came in some contrast to the fate of ciliated cells in other lung injury models where this cell population is
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also primarily responsible for airway repair in concert with EGFR
expression but depends on a marked proliferative response (14, 54).
The present findings therefore raised the unexpected possibility
that prolonged EGFR-dependent cell survival (not proliferation)
is critical for remodeling of epithelial structure toward a chronic
asthma/bronchitis phenotype. Support for this possibility was
obtained when we showed that EGFR blockade prevented ciliated
cell hyperplasia in vivo and caused ciliated epithelial cell apoptosis
in vitro. Additional study of airway epithelial cells cultured under
physiologic conditions indicated that ciliated epithelial cell survival
depends on uninterrupted EGFR signaling to PI3K. Otherwise, the
ciliated cells proceed toward programmed cell death (via caspase
activation) in a manner that appears analogous to virus-inducible
apoptosis (38). The fidelity of the present model to human disease
is supported by initial experiments that detect ciliated epithelial
cells with activated EGFR in airway sections from subjects with
asthma, but further studies will be needed to verify this finding and
extend it to other chronic airway diseases. Nonetheless, the present
findings indicate that the plasticity and responsiveness of ciliated
cells in the setting of airway damage and inflammation is an underappreciated but seminal feature of airway epithelial remodeling.
The second major set of findings of the present study was focused
on IL-13 signaling and the capacity of ciliated cells to transdifferentiate to goblet cells under IL-13 stimulation. This finding was
also unexpected, since previous work had suggested that IL-13 may
cause a decrease in ciliated cells and an increase in goblet cells, but
no apparent connection was drawn between the 2 phenomena (3, 5).
In the present work, we were able to capture snapshots of epithelial cells in vitro and in vivo that appear to be transitioning from
a ciliated to a goblet cell phenotype under pressure from IL-13. In
addition, we detected reciprocal increases in ciliated cell levels during IL-13 blockade in vivo. Additional cell lineage studies of this
process are needed to fully define the mechanism of transdifferentiation, but the evidence points to a program that carefully coordiThe Journal of Clinical Investigation

nates ciliated and goblet cell formation to achieve proper mucosal
immunity. Indeed, epithelial EGFR activation, ciliated cell hyperplasia, IL-13 production, and goblet cell metaplasia appear to develop together in time. This type of coordination is likely required for
efficient mucociliary function. The present results suggest that
abnormally prolonged IL-13 production may lead to goblet cell
metaplasia beyond the initial repair phase and so explain how goblet cell metaplasia may develop in this setting. Thus, genetic susceptibility to the development of persistent EGFR activation as well as
IL-13 production after viral infection may allow for the consequent
development of goblet cell metaplasia. Whether a similar paradigm
applies to other asthmagenic stimuli (e.g., allergen exposure) will
need further study in models that mimic the human condition.
Nonetheless, the fidelity of the present model to human disease is
again supported by initial experiments that detect ciliated-to-goblet
cell transdifferentiation in airway sections and cultured cells from
patients with COPD likely under the influence of IL-13.
Together, our results on EGFR- and IL-13–dependent signaling
provide a new paradigm for epithelial host defense and remodeling
(summarized in Figure 10) that should be useful for developing a
rational basis for therapies aimed at downregulating hypersecretory
conditions. Thus, tyrosine kinase inhibitors in general and EGFR
tyrosine kinase inhibitors in particular are being broadly developed
for use in conditions exhibiting abnormal epithelial architecture,
including asthma and COPD, but the cellular signaling context
for their application to airway disease was uncertain. The present
strategy utilized an irreversible inhibitor of EGFR tyrosine kinase
activity that showed efficacy in preventing epithelial hyperplasia in
a model of intestinal neoplasia (55). In that setting, the pharmacologic strategy was aimed at inhibiting epithelial proliferation, but
our findings indicate that interrupting antiapoptotic signals may be
the primary target in inflammatory airway disease. Further development of approaches for targeting EGFR (as well as those directed
at IL-13–dependent events) will also benefit from further defining

http://www.jci.org

Volume 116

Number 2

February 2006



Downloaded on July 24, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/25167

SFTFBSDIBSUJDMF
'JHVSF
4DIFNFGPSWJSVTJOEVDJCMF&('3BOE*-m
EFQFOEFOUQBUIXBZTDPOUSPMMJOHFQJUIFMJBMIPTU
SFTQPOTF BOE SFNPEFMJOH &('3 BDUJWBUJPO
XJUISFDFQUPSEJNFSJ[BUJPOBOESFDFQUPSUZSPTJOF
LJOBTFQIPTQIPSZMBUJPOMFBETUP(BCSFDSVJU
NFOU GPMMPXFE CZ 1*, BDUJWBUJPOUIBUDBVTFT
HFOFSBUJPOPGQIPTQIBUJEZMJOPTJUPM  QIPT
QIBUF 1*  1 BOEBDUJWBUJPOPG1%,BOE
UIFO"LUUIBUJOBDUJWBUFTQSPBQPQUPUJDGBDUPSTBU
UIFMFWFMPGUIFNJUPDIPOESJBBOEQSPNPUFDFMM
TVSWJWBM*-TJHOBMJOHBDUJWBUFT*34EFQFO
EFOUDBTDBEFUP&3,BOE4UBU XIJDIFBDI
DPOUSJCVUFUPVQSFHVMBUJPOPGHFOFT $-$"BOE
.6$ UIBUQSPNPUFDJMJBUPHPCMFUDFMMUSBOTEJG
GFSFOUJBUJPO6OEFSQIZTJPMPHJDDPOEJUJPOT UIFTF
QBUIXBZTNBZ JODPOKVODUJPOXJUI*'/EFQFO
EFOUBDUJWBUJPOPG4UBU MFBEUPQSPUFDUJPOGSPN
WJSBMJOGFDUJPO CVUJGUIFSFJTQFSTJTUFOUBDUJWBUJPO
JOBTVTDFQUJCMFHFOFUJDCBDLHSPVOE UIFTBNF
QBUIXBZTNBZMFBEUPDJMJBUFEDFMMIZQFSQMBTJB
BOEHPCMFUDFMMNFUBQMBTJB3BUJPOBMVTFPGTQF
DJGJDJOIJCJUPST FH &('3BOE*-3CMPDLFST 
NBZGVMMZSFTUPSFOPSNBMFQJUIFMJBMBSDIJUFDUVSF
(SC HSPXUIGBDUPSSFDFQUPSmCPVOE15&/ 
QIPTQIBUBTFBOEUFOTJOIPNPMPHVFEFMFUFEPO
DISPNPTPNF4PT TPOPGTFWFOMFTT

the signaling events that regulate airway epithelial cell apoptosis
and transdifferentiation. In that regard, we provide evidence that
downstream signaling to prevent epithelial cell apoptosis proceeds
through EGFR-dependent PI3K but not MEK/ERK activation based
on selective inhibition. This finding implies that the targeted pathway extends from EGFR homo- or heterodimerization and activation
of the receptor tyrosine kinase cytosolic domain to autophosphorylation of tyrosine resides within the cytoplasmic domain, docking of
Gab2/PI3K, and subsequent activation of Akt signaling (56).
As noted above, the present results for EGFR-PI3K survival signaling stand in some contrast to reports of EGFR and other signals to ERK1/2 to promote cell survival under other circumstances
(51). In particular, respiratory syncytial virus may trigger EGFR
and ERK1/2 activation (and IL-8 release) in cultured epithelial
cells during the acute infection, but these studies were performed
using transformed (A549) cells with necessarily altered death
pathways or in submerged cell cultures that do not differentiate
into ciliated epithelial cells (50). Nonetheless, acute infection with
respiratory syncytial virus (as well as SeV and influenza virus) may
promote epithelial cell survival in the acute setting based on chemokine-dependent activation of either PI3K/Akt or MEK/ERK signaling both in vitro (using well-differentiated mouse and human
cells) and in vivo (using a mouse model of acute infection) (38).
In contrast to the situation for acute infection, the present findings therefore highlight the change in epithelial survival signals in
the chronic setting and are again remarkable for using high-fidelity models in vitro and in vivo to establish that EGFR signals via
PI3K/Akt selectively regulate ciliated cell survival.
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The selective effect of PI3K but not MEK1/2 inhibition in the
present system may also indicate that there is little contribution
from the interaction of downstream signaling pathway through
positive- or negative-feedback mechanisms. There is, however, significant overlap between EGFR- and IL-13–signaling events despite
distinct outcomes. EGFR activation of a PI3K/Akt signal is directed
at preventing apoptosis, whereas IL-13 signaling to PI3K as well
as ERK1/2 and Stat6 are all directed toward increasing CLCA and
MUC gene expression to promote goblet cell formation (ref. 5 and
A.C. Patel, J.D. Morton, and M.J. Holtzman, unpublished observations). The distinct outcomes of EGFR and IL-13 activation of PI3K
and ERK1/2 are likely related to further diversity in downstream
signaling. For example, EGFR survival signals may be mediated by
Akt-dependent phosphorylation and inactivation of the proapoptotic factor BAD whereas other downstream targets of Akt may contribute to mucin gene expression (57, 58). The present results help
to lay the biologic basis for defining these downstream events.
The present results complement previous results suggesting that
Clara cells also give rise to mucous cells. Thus, allergen-induced goblet cell metaplasia is accompanied by morphologic and biochemical
evidence of CCSP-positive Clara cells containing mucous granules
in mice (22–24). Inhibitor effects were not reported in those studies,
but at least 1 report showed a decrease in Clara cell level concomitant
with an increase in goblet cell level consistent with Clara-to-goblet
cell transdifferentiation (22). Similarly, others used the rat CCSP
promoter to delete endogenous IL-13R signaling and downregulate mucous cell metaplasia in allergen-challenged mice (6). Given
the present results, residual metaplasia in that model may have been

http://www.jci.org

Volume 116

Number 2

February 2006

Downloaded on July 24, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/25167

SFTFBSDIBSUJDMF
derived from ciliated cells. However, comparison to the present results
is complicated by the change in stimulus (from allergen to virus) and
genetic background (from Balb/cJ to C57BL/6J). Moreover, IL-13
may regulate CCSP expression (Y. You and S. Brody, unpublished
observations, and ref. 25), and the rat CCSP promoter system may
not be specific for mouse Clara cell expression. In fact, significant
levels of CCSP-driven recombination can be found in ciliated airway
epithelial cells (59). Thus, it may be necessary to track other markers
of Clara cell lineage to fully define the relative contribution of Clara
versus ciliated cell populations to goblet cell metaplasia. We found
virus-induced decreases in Clara cell levels that were reversed by EGFR
blockade but unchanged after IL-13 inhibition, so the significance
of any Clara cell contribution to mucous cell metaplasia after viral
infection remains uncertain. Nonetheless, the present observations
of CCSP and β-tubulin colocalization with MUC5AC in mice and in
humans suggests that ciliated and Clara cells may each demonstrate
sufficient plasticity to contribute to mucous cell metaplasia.
Taken together, the present report extends the line of reasoning
that airway epithelial cells may be specially programmed for normal
immune defense (especially against respiratory viruses) and abnormally programmed in airway disease. Previous work focused on
other epithelial immune responses (notably interferon signaling)
and how the epithelium clears infection in the short term (60, 61),
whereas the present work focuses on EGFR and IL-13 and how the
epithelium responds in the long term. Similar to other epithelial
responses, the EGFR and IL-13 signals were likely developed to protect host epithelial cells from the lethal effect of viruses and to optimize mucosal immunity. As noted above (Figure 10), the epithelial
EGFR antiapoptotic system may protect the host cell (often the ciliated cell) from cytopathic effects that allow spread of infection. In
parallel, the IL-13 goblet cell system may direct increases in mucus
formation to aid mucociliary clearance of cellular and microbial
debris from the airway. Both of these strategies are likely achieved
in concert with epithelial interferon signaling that also protects the
host cell by inhibiting viral replication. The present work adds the
critical piece that demonstrates how, in some genetic settings, this
normally protective response may be skewed toward a persistent
response that results in a chronic asthma/bronchitis phenotype.
Further study is needed to determine whether this genetic susceptibility is linked to EGFR mutations that confer antiapoptotic signals and inhibitor sensitivity in lung cancer cells (62) or whether
persistent EGFR activation is connected to IFN signaling and
chronic Stat1 activation found in asthma (63), as may be the case in
other epithelial barriers (64). Nonetheless, the present results demonstrate that the abnormality in epithelial immune-response programming can be corrected by targeted inhibition of critical signaling steps. Treatment with EGFR tyrosine kinase inhibitors allows
for the ciliated cells to proceed toward programmed cell death in a
manner that appears analogous to virus-inducible apoptosis while
IL-13 blockade appears to prevent the transition from ciliated
to goblet cells. This new scheme thereby indicates that epithelial
remodeling toward an asthma/bronchitis phenotype depends on
both EGFR survival and IL-13 transdifferentiation signals such
that treatment to block both of these signals would be required to
fully restore the airway epithelium to its original architecture.
.FUIPET
Mice and viral inoculation. C57BL/6J and Balb/cJ mice were obtained from
Jackson Laboratory at 5 weeks of age and were maintained for study at 6–7
weeks of age as described previously (36–38) under protocols approved by
The Journal of Clinical Investigation

the Washington University Animal Studies Committee. SeV was grown in
embryonated hen eggs and harvested to provide a viral stock solution such
that 5000 EID50 (50% egg infectious dose) was equivalent to 2 × 105 PFUs.
This inoculum or an equivalent amount of UV-inactivated SeV was delivered intranasally in 30 μl PBS under ketamine/xylazine anesthesia. Under
these conditions, viral tissue levels are maximal at 3–5 days after inoculation, and viral clearance is complete by day 12 (36–38). Sentinel mice and
experimental control mice were handled identically to inoculated mice
and exhibited no serologic or histologic evidence of exposure to 11 rodent
pathogens (including SeV). For EGFR blockade, mice were treated with
EKB-569 (obtained from L.M. Greenberger, Wyeth Pharmaceuticals, Pearl
River, New York, USA; 20 mg/kg in pH 2.0 water given by gavage) or vehicle
control given daily for postinfection days 10–21. For IL-13 blockade, mice
were given subcutaneous injections of sIL-13Rα2-Fc (obtained from D.D.
Donaldson, Wyeth Ayerst, Cambridge, Massachusetts, USA; 200 μg/mouse
in PBS) or control Fc at 12, 14, 17, and 20 days after inoculation.
Histochemistry. Mouse lung was fixed by intratracheal instillation of 4%
paraformaldehyde at 25-cm H2O pressure, embedded in paraffin, and cut into
3-μm thick sections for H&E or immunostaining. For immunostaining, tissue
sections were deparaffinized, rehydrated in graded alcohol, and encircled with
a hydrophobic film (ImmEdge PEN; Vector Laboratories). For antigen retrieval, sections were digested with proteinase K (Sigma-Aldrich) at a final concentration of 40 μg/ml in PBS for 5 minutes and then treated in 3% hydrogen
peroxide in distilled water for 10 minutes to quench endogenous peroxidase
activity. Nonspecific protein binding was blocked with 3% BSA and 2% goat
serum in Tris-buffered saline (pH 8.0) with 0.2% Tween 20 (TBST) for 1 hour.
Primary antibodies were diluted in blocking buffer and incubated overnight
at 4°C at a final concentration of 0.05 or 0.1 μg/ml for human and mouse tissue sections, respectively. EGFR was detected using rabbit anti-human EGFR
antibody SC-03 (Santa Cruz Biotechnology Inc.) directed against amino
acid residues 1005–1016, which are identical to corresponding sequences in
murine EGFR. Phosphorylated EGFR (p-EGFR) was detected using rabbit
anti–p-EGFR (Tyr845) antibody 2231 (Cell Signaling Technology) directed
against phosphorylated Tyr845. For this antibody, final concentrations of 0.16
and 0.32 μg/ml were used for human and mouse tissues, respectively. Ciliated,
Clara, and goblet cells were identified using mouse anti–β-tubulin IV mAb
(Sigma-Aldrich), goat anti-CCSP antibody (Santa Cruz Biotechnology), and
mouse anti-human MUC5AC mAb 45M1 (Lab Vision Corp.), respectively.
To verify specificity, sections were also incubated with primary antibodies
that were preabsorbed with 10-fold excess of peptide antigen or with nonimmune rabbit IgG (Santa Cruz). After primary antibody binding, sections were
washed with TBST and then incubated with biotinylated goat anti-rabbit IgG
(2 μg/ml). Signals were amplified with the Elite ABC method and 3,3′-diaminobenzidine chromogen according to the manufacturer’s protocols (Vector
Laboratories). Sections were counterstained with hematoxylin, dehydrated,
and mounted with Cytoseal 60 (Stephens Scientific).
Immunof luorescence was performed in the same manner as
immunostaining for light microscopy except that tissues were frozen in Tissue-Tek OCT (Sakura Finetek Co.), sections were blocked with 2% donkey
serum (Jackson ImmunoResearch Laboratories Inc.), primary antibody binding was detected using CY-3– or FITC-conjugated antibodies (Jackson ImmunoResearch Laboratories Inc.) for 30 minutes at 25°C, and sections were
counterstained with Hoechst dye 33432 (Invitrogen Corp.). Sections were
imaged with light or immunofluorescent microscopy (BX-51; Olympus) interfaced to a digital photomicrography system (CCD Camera and MagnaFire
software, version 2; Optronix). Reporter was quantified by counting ciliated
cells in pulmonary airways per mm of basement membrane with analysis performed using the NIH Image program (http://rsb.info.nih.gov/nih-image), as
described previously (36, 37, 63). Confocal microscopy was performed using a
Zeiss laser scanning system with LSM-S10 software, version 3.2.
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Human tissue procurement and analysis. Asthmatic patients with and without glucocorticoid treatment and healthy control subjects were recruited,
characterized, and subjected to endobronchial biopsy as described previously (37, 63). Endobronchial biopsies were washed with PBS and incubated with 10% neutral buffered formalin for 18 hours at 25°C followed
by histochemistry as described above. In addition, we obtained lung tissue samples from COPD patients who were undergoing lung resection or
transplantation and processed them as described above. All human studies
were approved by the Washington University Human Studies Committee,
and all subjects gave informed consent.
Proliferation markers. For BrdU immunostaining, mice received BrdU
(100 mg/kg) intraperitoneally at 48 hours, 24 hours, and 4 hours prior to
euthanasia. BrdU was detected with an anti-BrdU staining kit (Zymed Laboratories Inc.) according to the manufacturer’s protocol. Ki67 immunostaining,
was performed with anti-Ki67 Ab (Novocastra) using the same protocol as
for EGFR immunostaining except for pretreatment of heat-induced antigen
retrieval using Antigen Unmasking Solution (Vector Laboratories). PCNA
staining was performed with biotinylated anti-mouse PCNA Ab (DakoCytomation) using the ABC method (Vector Laboratories).
Airway epithelial cell culture and treatment. Primary air-liquid interface cultures
of mTECs were established as described previously (53). Human airway epithelial cell cultures were established from tracheobronchial specimens harvested from lung explants of COPD patients undergoing transplantation and
from lung transplant donors without lung disease using the same culture
conditions. In all cases, cells were grown in basic medium (DMEM/Ham’s
F-12 with 30 mM HEPES, 4 mM L-glutamine, 3.5 mM NaHCO3, 0.01% Fungizone, and penicillin/streptomycin) supplemented with 10 μg/ml insulin,
10 μg/ml transferrin, 0.1 μg/ml cholera toxin, 25 ng/ml EGF (BD), 30 μg/ml
bovine pituitary extract, and 5% FBS in the upper and lower compartments.
After the cells developed transmembrane electrical resistance greater than
1000 Ohm/cm2, the air-liquid interface condition was established by washing the membrane with PBS and changing the medium in the lower compartment to basic medium supplemented with 2% NuSerum (BD Biosciences).
For EGFR stimulation, cells were incubated in basic medium for 24 hours and
then in basic medium containing EGF (1–100 ng/ml; Upstate Biotechnology) added to the upper and/or lower compartments for 10 minutes at 37°C.
EGFR signaling inhibitors or vehicle control (0.1 % DMSO) were added to the
lower compartments on a daily basis for long-term experiments or for 1.5–6
hours to the upper and lower compartments for short-term experiments.
EGFR tyrosine kinase inhibitor PD153035, MEK1/2 inhibitor PD98059,
EGFR tyrosine kinase inhibitor AG1478, and PI3K inhibitor LY294002 were
from Calbiochem, and z-VAD-fmk was from Enzyme Systems Products.
Recombinant human or mouse IL-13 from Preprotech was added to upper
and lower compartments at 24 hours before air-liquid interface conditions
and was maintained in the lower compartment throughout the experiment.
Western blotting. For whole lung analysis, the left lobe of mouse lung was
homogenized in RIPA buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1%
SDS in PBS) containing phosphatase inhibitor cocktail (Sigma-Aldrich). Tracheal tissue and mTECs were collected in cell lysis buffer containing 20 mM
Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton-X 100,
1.0 μg/ml leupeptin, 10 μg/ml aprotinin, 0.2 mM phenylmethylsulfonyl
fluoride, 1 mM sodium orthovanadate, 0.1 mM sodium fluoride, 2.5 mM
1. Grunig, G., et al. 1998. Requirement for IL-13 independently of IL-4 in experimental asthma. Science.
282:2261–2263.
2. Wills-Karp, M., et al. 1998. Interleukin-13: central
mediator of allergic asthma. Science. 282:2258–2261.
3. Laoukili, J., et al. 2001. IL-13 alters mucociliary differentiation and ciliary beating of human respiratory epithelial cells. J. Clin. Invest. 108:1817–1824.
doi:10.1172/JCI200113557.


sodium pyrophosphate, and 1 mM β–glycerophosphate. Cell lysates were
cleared by centrifugation, and supernatant proteins were separated on
4–15% gradient SDS-PAGE and transferred to PVDF membranes (Millipore). The membranes were blotted against antibodies to EGFR, p-EGFR,
p-ERK1/2, activated caspase-3, p-Stat6 (Cell Signaling Technology),
p-Akt (BD Biosciences), caspase-9 (Stressgen Biotechnologies), and β-actin
(Chemicon International). Primary antibody binding was detected with
secondary antibodies conjugated to horseradish peroxidase and enhanced
chemiluminescence (Amersham Pharmacia Biotech).
Immunocytochemistry. Cultured cells were washed twice with PBS at 4°C,
fixed in 4% paraformaldehyde for 10 minutes at 25°C, washed with PBS,
and permeabilized with ethanol:acetic acid (2:1, vol/vol) for 5 minutes at
–20°C for TUNEL reaction or with 0.2% Triton-X for 5 minutes at 25°C for
immunostaining. Permeabilized cells were then washed with PBS and subjected to the TUNEL reaction (Intergen Co.) or blocked with 2% fish gel for
1 hour at 25°C and incubated with rabbit anti-active caspase-3 (BD Biosciences), rabbit anti-EGFR (Santa Cruz Biotechnology Inc., rabbit anti–p-EGFR
(Cell Signaling Technology), mouse anti-β-tubulin IV, or rabbit anti–γ-tubulin
(Sigma-Aldrich) antibodies overnight at 4°C. Primary antibody binding was
detected with goat anti-mouse or donkey anti-rabbit FITC or CY3 secondary
antibody. Cells were counterstained with 4 μg/ml Hoescht 33258 (Invitrogen
Corp.) to check nuclear morphology, and then imaged as described above.
Flow cytometry. mTECs were cultured as above and removed from Transwell culture using cell dissociation solution (Sigma-Aldrich) containing
0.25% trypsin and 0.1% EDTA. Cells were washed with HBSS containing
0.2% BSA and incubated with 5 μg/ml JC-1 (Invitrogen Corp.) for 15 minutes at 25°C. Cells with mitochondrial membrane depolarization were
detected by a shift from low to high emission in green fluorescence (FL1)
using a FACSCalibur flow cytometer and CellQuest software (BD).
Electron microscopy. Cells on membranes were prepared for transmission
electron microscopy (TEM) as previously described (53). In brief, samples
were fixed with 2.5% glutaraldehyde and stained with 1.25% osmium
tetroxide. Cells were counterstained with 2.0% tannic acid, blocked for sectioning, and imaged on a Zeiss 902 model microscope.
Statistics. Values for histochemistry of mouse tissues were analyzed using
a 1-way analysis of variance (ANOVA) for a factorial experimental design.
If significance was achieved by 1-way analysis, post-ANOVA comparison
of means was performed using Scheffe’s F test. P < 0.05 was considered
statistically significant.
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